The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Homologous recombination deficiency (HRD): A biomarker for first-line (1L) platinum in advanced pancreatic ductal adenocarcinoma (PDAC).
 
Wungki Park
No Relationships to Disclose
 
Winston Wong
No Relationships to Disclose
 
Kenneth H. Yu
Consulting or Advisory Role - celgene; Merck Serono; Merrimack
 
Anna M. Varghese
Consulting or Advisory Role - Roche (I)
Research Funding - BioMed Valley Discoveries; Bristol-Myers Squibb; Illumina (I); Lilly; Silenseed; Verastem
Travel, Accommodations, Expenses - Roche (I)
 
Nadeem Riaz
Honoraria - PeerView
Speakers' Bureau - Illumina
Research Funding - Bristol-Myers Squibb; Pfizer
Travel, Accommodations, Expenses - Varian Medical Systems
 
Vinod P. Balachandran
No Relationships to Disclose
 
Imane H. El Dika
No Relationships to Disclose
 
Nitya Prabhakar Raj
Research Funding - Novartis (Inst); Xencor (Inst)
 
Danny Khalil
No Relationships to Disclose
 
Geoffrey Yuyat Ku
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Merck Sharp & Dohme
Research Funding - Arog (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck (Inst); Pieris Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Aduro Biotech; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Sharp & Dohme
 
Neil Howard Segal
Consulting or Advisory Role - Aduro Biotech; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; CStone Pharmaceuticals; EMD Serono; Gritstone Bio; Horizon Pharma; IFM Therapeutics; Imugene; Kyn therapeutics; Merck; Pfizer; Pieris Pharmaceuticals; PsiOxus Therapeutics; PureTech; Roche/Genentech; Synlogic; TRM Oncology
Research Funding - Bristol-Myers Squibb; Incyte; MedImmune; Merck; Pfizer; Roche/Genentech
 
Jia Li
No Relationships to Disclose
 
Sree Bhavani Chalasani
No Relationships to Disclose
 
Curtis Robert Chong
No Relationships to Disclose
 
David Paul Kelsen
No Relationships to Disclose
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - 3DMedcare; Agios; Alignmed; Amgen; Antengene; Aptus Clinical; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BiolineRx (I); Boston Scientific; BridgeBio Pharma; Bristol-Myers Squibb; CARsgen Therapeutics; CASI Pharmaceuticals; Celgene; Celsion; Cipla; CytomX Therapeutics (I); Daiichi Sankyo; Debiopharm Group; Delcath Systems; Eisai; EMD Serono (I); Exelixis; Genoscience Pharma; Gilead Sciences (I); Halozyme; Halozyme; Hengrui Pharmaceutical; Inovio Pharmaceuticals; Ipsen; Janssen (I); Jazz Pharmaceuticals; Kyowa Hakko Kirin; LAM Therapeutics; Lilly; Loxo (I); Medimmune; Merck Serono; Minapharma; Newlink Genetics (I); Novella Clinical; Onxeo; PCI Biotech; PCI Biotech; Pfizer (I); Pharmacyclics (I); Pharmacyte Biotech (I); Pieris Pharmaceuticals (I); QED Therapeutics; RedHill Biopharma; Roche; Sanofi; SERVIER; Silenseed (I); Sillajen; Sirtex Medical; Sirtex Medical; SOBI (I); Targovax (I); Tekmira; Tekmira; twoXAR; Vicus Therapeutics (I); Yakult Pharmaceutical; Yakult Pharmaceutical; Yiviva
Research Funding - Acta Biologica (Inst); Agios (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); MabVax (Inst); MedImmune (Inst); Momenta Pharmaceuticals (Inst); Novartis (Inst); OncoMed (Inst); OncoQuest (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Polaris
 
Michael F. Berger
Consulting or Advisory Role - Roche
Research Funding - Illumina
 
Nikolaus Schultz
No Relationships to Disclose
 
Christine A Iacobuzio-Donahue
No Relationships to Disclose
 
Eileen Mary O'Reilly
Consulting or Advisory Role - 3DMedcare (I); Agios (I); Alignmed (I); Amgen (I); Antengene (I); Aptus Clinical; Aptus Clinical (I); ASLAN Pharmaceuticals (I); Astellas Pharma (I); AstraZeneca (I); Bayer (I); BeiGene (I); BiolineRx; Boston Scientific (I); Bridgebio (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CARsgen Therapeutics (I); CASI Pharmaceuticals (I); CASI Pharmaceuticals (I); Celgene; Celgene (I); Celsion (I); Cipla (I); CytomX Therapeutics; Daiichi Sankyo (I); Debiopharm Group (I); Delcath Systems (I); Eisai (I); Exelixis (I); Genoscience Pharma (I); Gilead Sciences; Halozyme; Halozyme (I); Hengrui Medicine (I); Inovio Pharmaceuticals (I); Ipsen (I); Janssen; Jazz Pharmaceuticals (I); Kyowa Hakko Kirin (I); LAM Therapeutics (I); Lilly (I); Loxo; Merck (I); Merrimack; Minapharma (I); Newlink Genetics; Novella Clinical (I); Onxeo (I); PCI Biotech (I); Pfizer; Pharmacyclics; Pharmacyte Biotech; Pieris Pharmaceuticals; QED Therapeutics (I); RedHill Biopharma (I); Sanofi; Sanofi (I); Servier (I); Silenseed; Sillajen (I); Sirtex Medical (I); SOBI; Targovax; Tekmira (I); twoXAR; twoXAR (I); VAXIMM; Vicus Therapeutics (I); Yakult Pharmaceutical (I); Yakult Pharmaceutical (I); Yiviva (I)
Research Funding - Acta Biologica (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Halozyme (Inst); Mabvax (Inst); OncoQuest (Inst); OncoQuest (Inst); Roche (Inst)